Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather

Executive Summary

Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.


Related Content

France's Dynacure Gets VC Backing To Progress Antisense Candidate For Myopathy
Brii Bio: Partnering To Bring Innovation To China
Deal Watch Asia Focus: Merck Partners With Alibaba For Entry To Digital Health In China
Appointments: Top-Level Changes At J&J, Roche, Pierre Fabre, Nordic Nanovector, Inthera And DDF
SOTIO Aims To Become A Diverse Oncology Company
Venture Funding Deals: Two Companies With China Ties Raise $260m Each
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Finance Watch: Hua Medicine Raises $117.4m While Evaluating A Hong Kong IPO
Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts